Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

346 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity.
Dufva O, Koski J, Maliniemi P, Ianevski A, Klievink J, Leitner J, Pölönen P, Hohtari H, Saeed K, Hannunen T, Ellonen P, Steinberger P, Kankainen M, Aittokallio T, Keränen MAI, Korhonen M, Mustjoki S. Dufva O, et al. Among authors: korhonen m. Blood. 2020 Feb 27;135(9):597-609. doi: 10.1182/blood.2019002121. Blood. 2020. PMID: 31830245 Free PMC article.
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses.
Adnan Awad S, Dufva O, Ianevski A, Ghimire B, Koski J, Maliniemi P, Thomson D, Schreiber A, Heckman CA, Koskenvesa P, Korhonen M, Porkka K, Branford S, Aittokallio T, Kankainen M, Mustjoki S. Adnan Awad S, et al. Among authors: korhonen m. Leukemia. 2021 Apr;35(4):1087-1099. doi: 10.1038/s41375-020-01011-5. Epub 2020 Aug 11. Leukemia. 2021. PMID: 32782381 Free PMC article.
Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion.
Kaartinen T, Luostarinen A, Maliniemi P, Keto J, Arvas M, Belt H, Koponen J, Mäkinen PI, Loskog A, Mustjoki S, Porkka K, Ylä-Herttuala S, Korhonen M. Kaartinen T, et al. Among authors: korhonen m. Cytotherapy. 2017 Jun;19(6):689-702. doi: 10.1016/j.jcyt.2017.03.067. Epub 2017 Apr 11. Cytotherapy. 2017. PMID: 28411126 Free article.
Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion.
Kaartinen T, Luostarinen A, Maliniemi P, Keto J, Arvas M, Belt H, Koponen J, Mäkinen PI, Loskog A, Mustjoki S, Porkka K, Ylä-Herttuala S, Korhonen M. Kaartinen T, et al. Among authors: korhonen m. Cytotherapy. 2017 Sep;19(9):1130. doi: 10.1016/j.jcyt.2017.06.003. Epub 2017 Jun 20. Cytotherapy. 2017. PMID: 28645733 No abstract available.
ATMP-classified, scalable, autologous cell spray for the treatment of skin wounds and assessment of its effects on wound healing clinically and on a molecular level.
Nuutila K, Katayama S, Laitinen A, Siltanen A, Patrikoski M, Valtonen J, Kankainen M, Kerkelä E, Kaartinen T, Juteau S, Korhonen M, Vuola J, Kankuri E. Nuutila K, et al. Among authors: korhonen m. Burns. 2023 Aug;49(5):1144-1156. doi: 10.1016/j.burns.2022.09.006. Epub 2022 Sep 16. Burns. 2023. PMID: 36195485 Free article.
Immunomonitoring of MSC-Treated GvHD Patients Reveals Only Moderate Potential for Response Prediction but Indicates Treatment Safety.
Keto J, Kaartinen T, Salmenniemi U, Castrén J, Partanen J, Hänninen A, Korhonen M, Lähteenmäki K, Itälä-Remes M, Nystedt J. Keto J, et al. Among authors: korhonen m. Mol Ther Methods Clin Dev. 2018 Feb 8;9:109-118. doi: 10.1016/j.omtm.2018.02.001. eCollection 2018 Jun 15. Mol Ther Methods Clin Dev. 2018. PMID: 29516024 Free PMC article.
346 results